Cinacalcet Hydrochloride and Col-Probenecid

• Generic Name: cinacalcet
• Dosage Forms: n.a.
• Other Brand Names: Sensipar

Treatment of secondary hyperparathyroidism associated with chronic renal disease in patients who are undergoing hemodialysis or peritoneal dialysis.

Safety and efficacy in patients who are not undergoing dialysis have not been established.

May be used alone or in conjunction with vitamin D analogs and/or phosphate binders.

Effects on clinical outcomes remain to be fully determined. The primary finding of the EVOLVE trial (a lack of effect on mortality or major cardiovascular events ) is controversial because of study limitations.

Management of hypercalcemia associated with parathyroid carcinoma; designated an orphan drug by FDA for this use.

Treatment of hypercalcemia associated with primary hyperparathyroidism in patients who would be candidates for parathyroidectomy based on serum calcium concentrations but who are unable to undergo the surgery; designated an orphan drug by FDA for this use.

• Generic Name: probenecid
• Dosage Forms: n.a.
• Other Brand Names: Benemid

Reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks.

Management of gout when there are visible tophi or when serum urate concentrations exceed 8.5–9 mg/dL and patient has family history of tophi or low urate excretion.

Not usually recommended for management of asymptomatic hyperuricemia; however, some clinicians have suggested that therapy be initiated when serum urate concentrations exceed 9 mg/dL (by colorimetric method) because these concentrations often are associated with increased joint changes and renal complications.

Of no value in the treatment of acute gout attacks (due to lack of analgesic or anti-inflammatory activity).

Probenecid/colchicine fixed-dosage preparation has limited usefulness for prophylactic therapy because colchicine present exceeds the amount required by most patients.

Has been used effectively to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics, furosemide, ethacrynic acid, pyrazinamide, or ethambutol.

Not recommended to treat hyperuricemia secondary to cancer chemotherapy, radiation, or myeloproliferative neoplastic diseases because of increased risk of uric acid nephropathy.

Used for therapeutic advantage to increase concentrations of certain β-lactam anti-infectives in the treatment of gonorrhea, neurosyphilis, or pelvic inflammatory disease (PID); do not use alone for treatment of gonorrhea, neurosyphilis, or PID.

Used as an adjunct to IM cefoxitin for treatment of uncomplicated urogenital and anorectal gonorrhea in adults and adolescents; considered an alternative regimen by CDC.

Used as an adjunct to IM penicillin G procaine for treatment of neurosyphilis if compliance can be ensured; considered an alternative regimen by CDC.

Used as an adjunct to IM cefoxitin for treatment of PID; considered a regimen of choice by CDC.

Has been used in diagnosis of parkinsonian syndrome and mental depression.